Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Protara Therapeutics (TARA) Other Operating Expenses (2019 - 2022)

Protara Therapeutics' Other Operating Expenses history spans 3 years, with the latest figure at $29.5 million for Q4 2022.

  • Quarterly Other Operating Expenses changed N/A to $29.5 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $29.5 million through Sep 2023, changed N/A year-over-year, with the annual reading at $29.5 million for FY2022, N/A changed from the prior year.
  • Other Operating Expenses came in at $29.5 million for Q4 2022, up from -$8.8 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $29.5 million in Q4 2022 to a low of -$8.8 million in Q4 2020.
  • The 3-year median for Other Operating Expenses is -$4.0 million (2019), against an average of $3.2 million.
  • The largest YoY upside for Other Operating Expenses was 113.38% in 2020 against a maximum downside of 113.38% in 2020.
  • Protara Therapeutics' Other Operating Expenses stood at -$4.1 million in 2019, then plummeted by 113.38% to -$8.8 million in 2020, then soared by 435.09% to $29.5 million in 2022.
  • Per Business Quant, the three most recent readings for TARA's Other Operating Expenses are $29.5 million (Q4 2022), -$8.8 million (Q4 2020), and -$4.1 million (Q4 2019).